1,5-Naphthalenedisulfonate Salts for Cationic Steroidal Antimicrobials
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clinical use of antimicrobial peptides faces challenges such as high production costs, susceptibility to proteases, and deactivation by proteins and DNA in lung mucosa, necessitating the development of non-peptide mimics that maintain antibacterial activity while being stable and cost-effective.
Innovation Solution
Development of sulfonic acid addition salts of cationic steroidal antimicrobials (CSAs), specifically di-addition salts with 1,5-naphthalenedisulfonic acid (NDSA), which are solid, crystalline, and micronized, offering improved stability and simplified synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial peptides are used for clinical treatment, then broad-spectrum antibacterial activity is achieved, but production cost increases and susceptibility to proteases occurs
Solution Approach 1:
The patent creates non-peptide mimics (ceragenins) that copy the essential amphiphilic morphology and cationic charge distribution of antimicrobial peptides. By replicating the key structural features (hydrophobic face and cationic face) without using peptide bonds, the invention achieves comparable antibacterial activity while eliminating the need for expensive peptide synthesis and avoiding protease susceptibility.
Solution Approach 2:
The patent modifies the chemical parameters by replacing peptide backbones with steroidal or other non-peptide scaffolds. This parameter change maintains the essential amphiphilic characteristics (hydrophobicity and cationic charge) while fundamentally altering the molecular structure to be resistant to proteolytic degradation and easier to manufacture.
2Reliability
If antimicrobial peptides are used, then antibacterial activity is achieved, but stability to proteolytic degradation decreases
Solution Approach 1:
The patent copies only the essential functional morphology (amphiphilic structure with cationic and hydrophobic faces) rather than the peptide sequence itself. This allows the creation of molecules that perform the same antibacterial function without containing peptide bonds, thereby achieving complete resistance to proteolytic degradation while maintaining antibacterial activity.
Solution Approach 2:
The patent replaces fragile peptide structures with chemically stable non-peptide alternatives that do not require complex protection from proteases. The simplified structures are inherently stable and do not suffer from the degradation issues that plague peptide-based therapeutics.
3Reliability
If cationic steroidal antimicrobials are synthesized, then antimicrobial activity is achieved, but synthesis complexity increases
Solution Approach 1:
The patent simplifies the synthesis by changing the core scaffold from complex peptide sequences to steroidal or other rigid frameworks that require fewer synthetic steps. The cationic and hydrophobic functionalities are introduced through straightforward modifications to the core structure, dramatically reducing overall synthesis complexity.
Solution Approach 2:
The patent separates the essential functional elements (cationic charge and hydrophobic region) from the complex peptide backbone. By designing molecules where these elements are attached to simple core structures, the synthesis becomes modular and more manageable, reducing overall complexity while maintaining antibacterial activity.
Data Source
AI summary
Disclosed herein are acid addition salts of cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous salt forms are identified, such as 1,5-naphthalenedisulfonic acid addition salts and sulfate addition salts. The acid addition salts may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering acid addition salts of CSAs.